{"pmid":32360697,"pmcid":"PMC7190487","title":"Metformin in COVID-19: A possible role beyond diabetes.","text":["Metformin in COVID-19: A possible role beyond diabetes.","Diabetes Res Clin Pract","Sharma, Swati","Ray, Avik","Sadasivam, Balakrishnan","32360697"],"journal":"Diabetes Res Clin Pract","authors":["Sharma, Swati","Ray, Avik","Sadasivam, Balakrishnan"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360697","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.diabres.2020.108183","keywords":["covid-19","diabetes","drug repurposing","metformin","sars-cov-2"],"e_drugs":["Metformin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495537643520,"score":9.490897,"similar":[{"pmid":32347974,"title":"Metformin and COVID-19: A novel deal of an Old Drug.","text":["Metformin and COVID-19: A novel deal of an Old Drug.","In 2002, China witnessed the emergence of a severe acute respiratory disease caused by coronavirus SARS-CoV. Ten years later in 2012 a new version of the virus appeared in the Middle East known as Middle East Respiratory Syndrome Coronavirus MERS-CoV. At the end of 2019, the Chinese Center for Disease Control and Prevention (China CDC) recorded a pneumonia of unknown causes. Epidemiologically, the pneumonia was linked to a wet animal and seafood wholesale market in Wuhan, Hubei Province, China, later Known by COVID-19. The COVID-19 is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Till now the total number of confirmed cases is 2,709,483 in over 225 countries around the world. A recent report indicates that obesity may responsible for increasing the mortality of COVID-19 in Italy rather than in China. Here we would like to shed light on a new suggestion to decrease the mortality rate of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","El-Arabey, Amr Ahmed","Abdalla, Mohnad","32347974"],"abstract":["In 2002, China witnessed the emergence of a severe acute respiratory disease caused by coronavirus SARS-CoV. Ten years later in 2012 a new version of the virus appeared in the Middle East known as Middle East Respiratory Syndrome Coronavirus MERS-CoV. At the end of 2019, the Chinese Center for Disease Control and Prevention (China CDC) recorded a pneumonia of unknown causes. Epidemiologically, the pneumonia was linked to a wet animal and seafood wholesale market in Wuhan, Hubei Province, China, later Known by COVID-19. The COVID-19 is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Till now the total number of confirmed cases is 2,709,483 in over 225 countries around the world. A recent report indicates that obesity may responsible for increasing the mortality of COVID-19 in Italy rather than in China. Here we would like to shed light on a new suggestion to decrease the mortality rate of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["El-Arabey, Amr Ahmed","Abdalla, Mohnad"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32347974","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25958","keywords":["covid-19","diabetic","metformin","obesity","older","pneumonia"],"locations":["China","Wuhan","Hubei","China","Italy","China"],"countries":["Italy","China"],"countries_codes":["ITA|Italy","CHN|China"],"e_drugs":["Metformin"],"topics":["Treatment"],"weight":1,"_version_":1666138494928420865,"score":86.306335},{"pmid":32334502,"title":"The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment","text":["The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment","Multiple viral pathogens can pose a significant health risk to individuals. As a recent example, the beta-coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical to address this global concern. One such avenue that may prove to be exceedingly fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, mitochondrial dysfunction, and the onset of hyperinflammation, a significant disability associated with COVID-19. Furthermore, pathways that can activate mTOR may be necessary for anti-hepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with a greater understanding of this novel pathway, new treatments against several viral pathogens may successfully emerge.","Curr Neurovasc Res","Maiese, Kenneth","32334502"],"abstract":["Multiple viral pathogens can pose a significant health risk to individuals. As a recent example, the beta-coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical to address this global concern. One such avenue that may prove to be exceedingly fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, mitochondrial dysfunction, and the onset of hyperinflammation, a significant disability associated with COVID-19. Furthermore, pathways that can activate mTOR may be necessary for anti-hepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with a greater understanding of this novel pathway, new treatments against several viral pathogens may successfully emerge."],"journal":"Curr Neurovasc Res","authors":["Maiese, Kenneth"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32334502","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.2174/1567202617666200425205122","keywords":["amp activated protein kinase (ampk)","akt","covid-19","sars-cov-2","angiotensin converting enzyme 2","apoptosis","autophagy","coronaviruses","cytokines","diabetes mellitus","inflammation","influenza","interferons","interleukins","mtor complex 1 (mtorc1)","mtor complex 2 (mtorc2)","macrophage inflammatory protein 1-alpha (mip-1alpha)","mechanistic target of rapamycin (mtor)","metformin","monocyte chemoattractant protein 1 (mcp-1)","oxidative stress","tumor necrosis factor-alpha","virion"],"locations":["Rapamycin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494085365762,"score":65.30084},{"pmid":32382358,"pmcid":"PMC7204191","title":"COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher's Stone?","text":["COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher's Stone?","Corona virus infectious disease (COVID-19) is a new pandemic. In subjects with diabetes mellitus, infection may be more frequent and severe. We discuss the potential contribution of two traditional oral antidiabetic agents, metformin and pioglitazone, to the improvement of liver injury in COVID-19. Clearly, further experience is needed to shed light on these hypotheses.","Diabetes Ther","Penlioglou, Theano","Papachristou, Stella","Papanas, Nikolaos","32382358"],"abstract":["Corona virus infectious disease (COVID-19) is a new pandemic. In subjects with diabetes mellitus, infection may be more frequent and severe. We discuss the potential contribution of two traditional oral antidiabetic agents, metformin and pioglitazone, to the improvement of liver injury in COVID-19. Clearly, further experience is needed to shed light on these hypotheses."],"journal":"Diabetes Ther","authors":["Penlioglou, Theano","Papachristou, Stella","Papanas, Nikolaos"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32382358","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s13300-020-00830-0","keywords":["antidiabetic agents","corona virus infectious disease","diabetes mellitus","metformin","pioglitazone","treatment"],"e_drugs":["Pioglitazone","Metformin"],"topics":["Treatment"],"weight":1,"_version_":1666419683255910400,"score":65.18076},{"pmid":32339534,"pmcid":"PMC7195096","title":"COVID-19 and diabetes: is metformin a friend or foe?","text":["COVID-19 and diabetes: is metformin a friend or foe?","Diabetes Res Clin Pract","Ursini, Francesco","Ciaffi, Jacopo","Paola Landini, Maria","Meliconi, Riccardo","32339534"],"journal":"Diabetes Res Clin Pract","authors":["Ursini, Francesco","Ciaffi, Jacopo","Paola Landini, Maria","Meliconi, Riccardo"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339534","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.diabres.2020.108167","e_drugs":["Metformin"],"topics":["Mechanism"],"weight":1,"_version_":1666138494182883330,"score":63.60551},{"pmid":32441299,"title":"Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: Possible therapeutic implication in COVID-19.","text":["Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: Possible therapeutic implication in COVID-19.","Due to the lack of efficient therapeutic options and clinical trial limitations, the FDA approved drugs can be a good choice to handle Coronavirus disease (COVID-19). Many reports have enough evidence for the use of FDA-approved drugs which have inhibitory potential against target proteins of SARS-CoV-2. Here, we utilized a structure-based drug design approach to find possible drug candidates from the existing pool of FDA-approved drugs and checked their effectiveness against the SARS-CoV-2. We performed virtual screening of the FDA approved drugs against the main protease (Mpro) of SARS-CoV-2, an essential protein, and a potential drug target. Using well-defined computational methods, we identified Glecaprevir and Maraviroc as the best inhibitors CoV-2 Mpro. Both drugs bind to the substrate-binding pocket of SARS-CoV-2 Mpro and form a significant number of non-covalent interactions. Glecaprevir and Maraviroc bind to the conserved substrate-binding pocket of SARS-CoV-2 Mpro. This work provides sufficient evidence for the use of Glecaprevir and Maraviroc for the therapeutic management of COVID-19.","Biosci Rep","Shamsi, Anas","Mohammad, Taj","Anwar, Saleha","Alajmi, Mohamed","Hussain, Afzal","Rehman, Md Tabish","Islam, Asimul","Hassan, Md Imtaiyaz","32441299"],"abstract":["Due to the lack of efficient therapeutic options and clinical trial limitations, the FDA approved drugs can be a good choice to handle Coronavirus disease (COVID-19). Many reports have enough evidence for the use of FDA-approved drugs which have inhibitory potential against target proteins of SARS-CoV-2. Here, we utilized a structure-based drug design approach to find possible drug candidates from the existing pool of FDA-approved drugs and checked their effectiveness against the SARS-CoV-2. We performed virtual screening of the FDA approved drugs against the main protease (Mpro) of SARS-CoV-2, an essential protein, and a potential drug target. Using well-defined computational methods, we identified Glecaprevir and Maraviroc as the best inhibitors CoV-2 Mpro. Both drugs bind to the substrate-binding pocket of SARS-CoV-2 Mpro and form a significant number of non-covalent interactions. Glecaprevir and Maraviroc bind to the conserved substrate-binding pocket of SARS-CoV-2 Mpro. This work provides sufficient evidence for the use of Glecaprevir and Maraviroc for the therapeutic management of COVID-19."],"journal":"Biosci Rep","authors":["Shamsi, Anas","Mohammad, Taj","Anwar, Saleha","Alajmi, Mohamed","Hussain, Afzal","Rehman, Md Tabish","Islam, Asimul","Hassan, Md Imtaiyaz"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441299","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1042/BSR20201256","keywords":["coronavirus disease 2019","fda approved drugs","sars-cov-2","drug repurposing","molecular docking","virtual screening"],"locations":["Maraviroc","Maraviroc","Maraviroc","Maraviroc"],"e_drugs":["Maraviroc","ABT-493"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119461646336,"score":61.84655}]}